ContraFect_LOGO_Web.jpg
Contrafect Announces Publication of Exebacase Phase 2 Study Results in the Journal of Clinical Investigation
June 17, 2020 07:30 ET | ContraFect Corporation
Phase 2 study results demonstrated the potential clinical benefit of exebacase, when used in addition to existing antibiotics, for the treatment of life-threatening MRSA bacteremia Exebacase Phase...
ContraFect_LOGO_Web.jpg
ContraFect Announces Appointment of Lishan Aklog, M.D. to Board of Directors
June 15, 2020 07:30 ET | ContraFect Corporation
YONKERS, N.Y., June 15, 2020 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs),...
ContraFect_LOGO_Web.jpg
ContraFect Corporation Announces Private Placement of Common Stock and Warrants to Pfizer Inc.
May 26, 2020 07:30 ET | ContraFect Corporation
YONKERS, N.Y., May 26, 2020 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on discovering and developing direct lytic agents for the...
ContraFect_LOGO_Web.jpg
ContraFect Reports First Quarter 2020 Financial Results and Provides Business Update
May 15, 2020 07:30 ET | ContraFect Corporation
YONKERS, N.Y., May 15, 2020 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs),...
Pomerantz LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of Common Stock of TerraForm Power, Inc. – TERP
September 27, 2017 11:00 ET | Pomerantz LLP
NEW YORK, Sept. 27, 2017 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that the United States District Court for the Southern District of New York has approved the following announcement of a proposed...